Hebo Pharma announced that its anti-CTLA-4 antibody (HBM4003) has completed its first patient medication in an open phase I study (study number 4003.
2) for patients with advanced melanoma and other solid tumors in China
In this study, HBM4003 was used in combination with teriprizumab (PD-1 antibody) to evaluate its safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and preliminary efficacy in the treatment of solid tumors
A month ago, the National Medical Products Administration (NMPA) also approved a clinical trial application for the combination of HBM4003 and PD-1 antibody/chemotherapy for the treatment of patients with advanced non-small cell lung cancer and other solid tumors
Professor Guo Jun, deputy dean of Peking University Cancer Hospital, deputy director of the Beijing Institute of Cancer Prevention and Treatment, and director of the Department of Melanoma, said: “In China, due to the special subtype of melanoma, the current treatments have problems such as poor prognosis and high mortality.
The effective rate of PD-1 single-agent immunotherapy is only about 16%
How to improve the effective rate of treatment through innovative solutions and further improve the survival of patients is currently an urgent problem to be solved
With the development of this research with Platinum Medicine, we It is expected to provide more effective and safer treatment options for Chinese melanoma and other solid tumor patients in the near future
"HBM4003 is a new generation of anti-CTLA-4 antibody.
Based on its unique mechanism of action, it has shown good safety and strong anti-tumor activity in preclinical studies
" Founder, Chairman and CEO of Hebo Medicine Dr.
Wang Jinsong said, “There are about 4 million new cancer patients in China every year, and there is an urgent need for innovative drugs and new solutions for cancer treatment
We will actively promote the multi-center clinical research and development process of HBM4003 for multiple cancers, so that the world Cancer patients can extend their lives and improve their quality of life through innovative drugs